Cost-benefit analysis of Haemophilus influenzae type b vaccination in children in Spain

F. Javier Jiménez, Pilar Guallar-Castillón, Carlos Rubio Terrés, Eliseo Guallar

Research output: Contribution to journalArticle

Abstract

Objective: Invasive disease caused by Haemophilus influenzae type b (Hib), including meningitis, pneumonia, sepsis and epiglottitis, is associated with high mortality and serious neurological sequelae in children under 5 years of age. The availability of an efficacious vaccine suggests the need to perform an economic evaluation of its use. The objective of this study was to evaluate the costs and benefits of introducing a universal vaccination programme for children under 1 year of age in Spain. Design & Setting: A cost-benefit analysis (CBA) was conducted over a 5-year period from the societal perspective in the Spanish healthcare setting. Both direct and indirect costs were included in the analysis [using 1996 Spanish pesetas (Pta); Pta 126.5 = $US1 in April 1996]. Patients and participants: The target population used for cost and benefit estimation was the 384 883 Spaniards aged 1 year or less in the last Spanish Population and Housing Census of 1991. Main outcome measures and results: The introduction of the universal Hib vaccination programme would imply vaccinating 346 395 children under 1 year of age, with a global expense of Pta2 444 855 910. For an average incidence of 15 cases of invasive disease per 100 000 children per year nationwide, the programme would prevent 219 cases of invasive disease and 8 deaths over a 5-year period, with a benefit of Pta2 182 868 907, a net benefit (i.e. benefit minus cost) of -Pta261 987 003, a benefit/cost ratio of 0.89 and a benefit per case prevented of -Pta1 196 288. Benefit/cost ratios above 1 would be obtained in the regions of highest incidence of invasive disease. Conclusion: The decision to implement a universal vaccination programme should not be based only on economic factors, but our results suggest that the economic returns of the programme for children under 1 year of age in Spain would be at least of a similar magnitude as its expenses.

Original languageEnglish (US)
Pages (from-to)75-83
Number of pages9
JournalPharmacoEconomics
Volume15
Issue number1
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Haemophilus influenzae type b
Spain
Cost-Benefit Analysis
Vaccination
Economics
Epiglottitis
Health Services Needs and Demand
Incidence
Censuses
Meningitis
Sepsis
Pneumonia
Vaccines
Outcome Assessment (Health Care)
Delivery of Health Care
Costs and Cost Analysis
Mortality
Population

ASJC Scopus subject areas

  • Pharmacology
  • Medicine (miscellaneous)

Cite this

Cost-benefit analysis of Haemophilus influenzae type b vaccination in children in Spain. / Jiménez, F. Javier; Guallar-Castillón, Pilar; Terrés, Carlos Rubio; Guallar, Eliseo.

In: PharmacoEconomics, Vol. 15, No. 1, 1999, p. 75-83.

Research output: Contribution to journalArticle

Jiménez, F. Javier ; Guallar-Castillón, Pilar ; Terrés, Carlos Rubio ; Guallar, Eliseo. / Cost-benefit analysis of Haemophilus influenzae type b vaccination in children in Spain. In: PharmacoEconomics. 1999 ; Vol. 15, No. 1. pp. 75-83.
@article{009e26891ede430cbe6b441723fc317a,
title = "Cost-benefit analysis of Haemophilus influenzae type b vaccination in children in Spain",
abstract = "Objective: Invasive disease caused by Haemophilus influenzae type b (Hib), including meningitis, pneumonia, sepsis and epiglottitis, is associated with high mortality and serious neurological sequelae in children under 5 years of age. The availability of an efficacious vaccine suggests the need to perform an economic evaluation of its use. The objective of this study was to evaluate the costs and benefits of introducing a universal vaccination programme for children under 1 year of age in Spain. Design & Setting: A cost-benefit analysis (CBA) was conducted over a 5-year period from the societal perspective in the Spanish healthcare setting. Both direct and indirect costs were included in the analysis [using 1996 Spanish pesetas (Pta); Pta 126.5 = $US1 in April 1996]. Patients and participants: The target population used for cost and benefit estimation was the 384 883 Spaniards aged 1 year or less in the last Spanish Population and Housing Census of 1991. Main outcome measures and results: The introduction of the universal Hib vaccination programme would imply vaccinating 346 395 children under 1 year of age, with a global expense of Pta2 444 855 910. For an average incidence of 15 cases of invasive disease per 100 000 children per year nationwide, the programme would prevent 219 cases of invasive disease and 8 deaths over a 5-year period, with a benefit of Pta2 182 868 907, a net benefit (i.e. benefit minus cost) of -Pta261 987 003, a benefit/cost ratio of 0.89 and a benefit per case prevented of -Pta1 196 288. Benefit/cost ratios above 1 would be obtained in the regions of highest incidence of invasive disease. Conclusion: The decision to implement a universal vaccination programme should not be based only on economic factors, but our results suggest that the economic returns of the programme for children under 1 year of age in Spain would be at least of a similar magnitude as its expenses.",
author = "Jim{\'e}nez, {F. Javier} and Pilar Guallar-Castill{\'o}n and Terr{\'e}s, {Carlos Rubio} and Eliseo Guallar",
year = "1999",
doi = "10.2165/00019053-199915010-00005",
language = "English (US)",
volume = "15",
pages = "75--83",
journal = "PharmacoEconomics",
issn = "1170-7690",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Cost-benefit analysis of Haemophilus influenzae type b vaccination in children in Spain

AU - Jiménez, F. Javier

AU - Guallar-Castillón, Pilar

AU - Terrés, Carlos Rubio

AU - Guallar, Eliseo

PY - 1999

Y1 - 1999

N2 - Objective: Invasive disease caused by Haemophilus influenzae type b (Hib), including meningitis, pneumonia, sepsis and epiglottitis, is associated with high mortality and serious neurological sequelae in children under 5 years of age. The availability of an efficacious vaccine suggests the need to perform an economic evaluation of its use. The objective of this study was to evaluate the costs and benefits of introducing a universal vaccination programme for children under 1 year of age in Spain. Design & Setting: A cost-benefit analysis (CBA) was conducted over a 5-year period from the societal perspective in the Spanish healthcare setting. Both direct and indirect costs were included in the analysis [using 1996 Spanish pesetas (Pta); Pta 126.5 = $US1 in April 1996]. Patients and participants: The target population used for cost and benefit estimation was the 384 883 Spaniards aged 1 year or less in the last Spanish Population and Housing Census of 1991. Main outcome measures and results: The introduction of the universal Hib vaccination programme would imply vaccinating 346 395 children under 1 year of age, with a global expense of Pta2 444 855 910. For an average incidence of 15 cases of invasive disease per 100 000 children per year nationwide, the programme would prevent 219 cases of invasive disease and 8 deaths over a 5-year period, with a benefit of Pta2 182 868 907, a net benefit (i.e. benefit minus cost) of -Pta261 987 003, a benefit/cost ratio of 0.89 and a benefit per case prevented of -Pta1 196 288. Benefit/cost ratios above 1 would be obtained in the regions of highest incidence of invasive disease. Conclusion: The decision to implement a universal vaccination programme should not be based only on economic factors, but our results suggest that the economic returns of the programme for children under 1 year of age in Spain would be at least of a similar magnitude as its expenses.

AB - Objective: Invasive disease caused by Haemophilus influenzae type b (Hib), including meningitis, pneumonia, sepsis and epiglottitis, is associated with high mortality and serious neurological sequelae in children under 5 years of age. The availability of an efficacious vaccine suggests the need to perform an economic evaluation of its use. The objective of this study was to evaluate the costs and benefits of introducing a universal vaccination programme for children under 1 year of age in Spain. Design & Setting: A cost-benefit analysis (CBA) was conducted over a 5-year period from the societal perspective in the Spanish healthcare setting. Both direct and indirect costs were included in the analysis [using 1996 Spanish pesetas (Pta); Pta 126.5 = $US1 in April 1996]. Patients and participants: The target population used for cost and benefit estimation was the 384 883 Spaniards aged 1 year or less in the last Spanish Population and Housing Census of 1991. Main outcome measures and results: The introduction of the universal Hib vaccination programme would imply vaccinating 346 395 children under 1 year of age, with a global expense of Pta2 444 855 910. For an average incidence of 15 cases of invasive disease per 100 000 children per year nationwide, the programme would prevent 219 cases of invasive disease and 8 deaths over a 5-year period, with a benefit of Pta2 182 868 907, a net benefit (i.e. benefit minus cost) of -Pta261 987 003, a benefit/cost ratio of 0.89 and a benefit per case prevented of -Pta1 196 288. Benefit/cost ratios above 1 would be obtained in the regions of highest incidence of invasive disease. Conclusion: The decision to implement a universal vaccination programme should not be based only on economic factors, but our results suggest that the economic returns of the programme for children under 1 year of age in Spain would be at least of a similar magnitude as its expenses.

UR - http://www.scopus.com/inward/record.url?scp=0032938681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032938681&partnerID=8YFLogxK

U2 - 10.2165/00019053-199915010-00005

DO - 10.2165/00019053-199915010-00005

M3 - Article

VL - 15

SP - 75

EP - 83

JO - PharmacoEconomics

JF - PharmacoEconomics

SN - 1170-7690

IS - 1

ER -